Amicus Therapeutics Announces Second Quarter 2019 Financial Results and Corporate Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil pares losses as market weighs Saudi supply concerns, Middle East tensions
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Amicus Therapeutics (FOLD) Misses Q2 EPS by 3c
August 8, 2019 7:20 AM EDTAmicus Therapeutics (NASDAQ: FOLD) reported Q2 EPS of ($0.36), $0.03 worse than the analyst estimate of ($0.33). Revenue for the quarter came in at $44.1 million versus the consensus estimate of $41.13 million.
2019 Financial Guidance:
For the full-year 2019 the Company anticipates total Galafold revenue... More
